SlideShare una empresa de Scribd logo
1 de 18
A Tiered Approach to
Integrating Genomic Tests
     Into Your Practice
Definition
Tiered Approach: Types
Genomic Tests: DNA screening test
Practice: Giving a diagnosis and prescribing a
treatment for medical condition

Combine DNA screening with medical treatment
to test the probability of certain disease.
Initiation
Office of Public Health Genomics at the Centers
for Disease Control and Prevention (CDC)
A New Era
Medicine informed by new "personalization"
tools in diagnosis, management, and prevention
of many diseases of public health significance.

However,

The mere availability of a health application
does not necessarily imply evidence of efficacy.
the CDC Office of Public Health Genomics has
recently created an evolving list of health-
related genomic tests and family health history
applications
                     3 Tier
1st   Tier
1st Tier
Applications are recommended for clinical use
by evidence-based panels and are supported by
a systematic review of evidence establishing the
validity and utility of these tests for their
intended use.
• Newborn screening

• BRCA1 and BRCA2

• Colorectal cancer surveillance
• evidence-based recommendation from the
  Evaluation of Genomic Applications in Practice
  and Prevention (EGAPP)



http://www.egappreviews.org/recommendations/index.htm
2nd   Tier
2nd Tier
Applications have evidence establishing validity
and promising utility, but they lack evidence-
based recommendations for their use, or
evidence-based panels have simply found
insufficient evidence.
• pharmacogenomic testing individualization of
  the choice or dose of a drug.



• Family history of Diabetes Mellitus
3rd Tier
Genomic and family health history applications
have not demonstrated adequate analytic
validity, clinical validity, or clinical utility.
Such applications are not ready for routine
practice but may be considered in clinical and
population research.

• whole genome sequencing/next-generation
  sequencing
Summary
"personalization“
Prevention

Ẋ ready for "prime time.“
Ẋ Lack of evidence
Web Resources

CDC. Public Health Genomics. Genetic Testing
CDC. Tier 1 Genomic and Family Health History Applications.
CDC. Tier 2 Genomic and Family Health History Applications.
CDC. Tier 3 Genomic and Family Health History Applications.
Michael Scott Bowen

Scott Bowen is the deputy director of the Office of Public Health
Genomics.
He earned his Masters of Public Health degree in Epidemiology from Tulane
University.
Mr. Bowen came to CDC under the Outstanding Scholar Program in 1992 and
had previously served on active duty as a non-commissioned officer with the
U.S. Army. His past CDC roles included service as the Management Officer for
the CDC/OD offices and as the deputy director for the Division of Public
Health Surveillance and Informatics. He has also worked for the Agency for
Toxic Substances and Disease Registry where he served as an epidemiologist
and as deputy chief of the Health Investigations Branch.
Thank you

Más contenido relacionado

La actualidad más candente

HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]Mary Beth Levin
 
Gail Hodgins Resume December 2015
Gail Hodgins Resume December 2015Gail Hodgins Resume December 2015
Gail Hodgins Resume December 2015Gail Hodgins
 
Precision Medicine: Research Presentation
Precision Medicine: Research PresentationPrecision Medicine: Research Presentation
Precision Medicine: Research PresentationShelagh McLellan
 
Rules of Engagement in Drug Development: Activating the Patient Voice
Rules of Engagement in Drug Development: Activating the Patient VoiceRules of Engagement in Drug Development: Activating the Patient Voice
Rules of Engagement in Drug Development: Activating the Patient VoiceNational Alopecia Areata Foundation
 
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...Covance
 
Dr. Patrick Webb - Coordinated, National Transboundary Disease Response Plan
Dr. Patrick Webb - Coordinated, National Transboundary Disease Response PlanDr. Patrick Webb - Coordinated, National Transboundary Disease Response Plan
Dr. Patrick Webb - Coordinated, National Transboundary Disease Response PlanJohn Blue
 
cohort study
cohort studycohort study
cohort studybunu lama
 
Problems in nursing, health, and social
Problems in nursing, health, and socialProblems in nursing, health, and social
Problems in nursing, health, and socialkuldeep amin
 
Antibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International ImperativeAntibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International ImperativePYA, P.C.
 
STSI-20160516-precision-medicine-infographic
STSI-20160516-precision-medicine-infographicSTSI-20160516-precision-medicine-infographic
STSI-20160516-precision-medicine-infographicVicki Smith
 
Barriers to Participation in Cancer Trials
Barriers to Participation in Cancer TrialsBarriers to Participation in Cancer Trials
Barriers to Participation in Cancer TrialsOncoguia
 
Medical Genetics
Medical GeneticsMedical Genetics
Medical GeneticsSara Rodas
 

La actualidad más candente (19)

HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]HIVProjectProgressPoster[1]
HIVProjectProgressPoster[1]
 
Evaluating the Use of Performance Measurement Among Older Adults 4.25.08
Evaluating the Use of Performance Measurement Among Older Adults 4.25.08Evaluating the Use of Performance Measurement Among Older Adults 4.25.08
Evaluating the Use of Performance Measurement Among Older Adults 4.25.08
 
Gail Hodgins Resume December 2015
Gail Hodgins Resume December 2015Gail Hodgins Resume December 2015
Gail Hodgins Resume December 2015
 
Precision Medicine: Research Presentation
Precision Medicine: Research PresentationPrecision Medicine: Research Presentation
Precision Medicine: Research Presentation
 
Rules of Engagement in Drug Development: Activating the Patient Voice
Rules of Engagement in Drug Development: Activating the Patient VoiceRules of Engagement in Drug Development: Activating the Patient Voice
Rules of Engagement in Drug Development: Activating the Patient Voice
 
doc
docdoc
doc
 
A "Talk" with Purpose
A "Talk" with PurposeA "Talk" with Purpose
A "Talk" with Purpose
 
SGIM Poster-Final
SGIM Poster-FinalSGIM Poster-Final
SGIM Poster-Final
 
RML Rendezvous: Transcending Borders Globally
RML Rendezvous: Transcending Borders GloballyRML Rendezvous: Transcending Borders Globally
RML Rendezvous: Transcending Borders Globally
 
COVID-19 Vaccine Trials: Why we still need them?
COVID-19 Vaccine Trials: Why we still need them?COVID-19 Vaccine Trials: Why we still need them?
COVID-19 Vaccine Trials: Why we still need them?
 
Dr. Andre Mitchell's CV
Dr. Andre Mitchell's CVDr. Andre Mitchell's CV
Dr. Andre Mitchell's CV
 
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...
The Increasing Importance of Patient Reported Outcomes and the Patient Voice ...
 
Dr. Patrick Webb - Coordinated, National Transboundary Disease Response Plan
Dr. Patrick Webb - Coordinated, National Transboundary Disease Response PlanDr. Patrick Webb - Coordinated, National Transboundary Disease Response Plan
Dr. Patrick Webb - Coordinated, National Transboundary Disease Response Plan
 
cohort study
cohort studycohort study
cohort study
 
Problems in nursing, health, and social
Problems in nursing, health, and socialProblems in nursing, health, and social
Problems in nursing, health, and social
 
Antibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International ImperativeAntibiotic Stewardship: A National and International Imperative
Antibiotic Stewardship: A National and International Imperative
 
STSI-20160516-precision-medicine-infographic
STSI-20160516-precision-medicine-infographicSTSI-20160516-precision-medicine-infographic
STSI-20160516-precision-medicine-infographic
 
Barriers to Participation in Cancer Trials
Barriers to Participation in Cancer TrialsBarriers to Participation in Cancer Trials
Barriers to Participation in Cancer Trials
 
Medical Genetics
Medical GeneticsMedical Genetics
Medical Genetics
 

Similar a A tiered approach to integrating genomic tests into

Genomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdfGenomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdfshinycthomas
 
Noninvasive prenatal testing_for_fetal_aneuploidy
Noninvasive prenatal testing_for_fetal_aneuploidyNoninvasive prenatal testing_for_fetal_aneuploidy
Noninvasive prenatal testing_for_fetal_aneuploidyAsha Reddy
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningJohnJulie1
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningAnonIshanvi
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningEditorSara
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer ScreeningNainaAnon
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screeningdaranisaha
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screeningsemualkaira
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screeningsemualkaira
 
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdfCancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdfProRelix Research
 
Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Current Concepts in Laboratory Testing to Guide Antimicrobial TherapyCurrent Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Current Concepts in Laboratory Testing to Guide Antimicrobial TherapyPathogens Outlook
 
Case control
Case controlCase control
Case controlBabahgaru
 
How evidence affects clinical practice in egypt
How evidence affects clinical practice in egyptHow evidence affects clinical practice in egypt
How evidence affects clinical practice in egyptWafaa Benjamin
 
Epcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesEpcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesDr Ghaiath Hussein
 
Impact Of Computer Software Appplication On Medication Therapy Adherence
Impact Of Computer Software Appplication On Medication Therapy AdherenceImpact Of Computer Software Appplication On Medication Therapy Adherence
Impact Of Computer Software Appplication On Medication Therapy AdherenceYayra Nyoagbe
 
Diagnosis Of Hep C Update Aug%20 09pdf
Diagnosis Of Hep C Update Aug%20 09pdfDiagnosis Of Hep C Update Aug%20 09pdf
Diagnosis Of Hep C Update Aug%20 09pdfusapuka
 
C04 P02 CRITERIA FOR SCREENING TESTS.ppt
C04 P02 CRITERIA FOR SCREENING TESTS.pptC04 P02 CRITERIA FOR SCREENING TESTS.ppt
C04 P02 CRITERIA FOR SCREENING TESTS.pptsanakhader3
 

Similar a A tiered approach to integrating genomic tests into (20)

Genomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdfGenomics-health, Pharmacogenomics.pdf
Genomics-health, Pharmacogenomics.pdf
 
healthcare
healthcarehealthcare
healthcare
 
screening.ppt
screening.pptscreening.ppt
screening.ppt
 
Noninvasive prenatal testing_for_fetal_aneuploidy
Noninvasive prenatal testing_for_fetal_aneuploidyNoninvasive prenatal testing_for_fetal_aneuploidy
Noninvasive prenatal testing_for_fetal_aneuploidy
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
Principles of Cancer Screening
Principles of Cancer ScreeningPrinciples of Cancer Screening
Principles of Cancer Screening
 
chapter2-191105204556.pdf
chapter2-191105204556.pdfchapter2-191105204556.pdf
chapter2-191105204556.pdf
 
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdfCancer Clinical Trials_ USA Scenario and Study Designs.pdf
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
 
Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Current Concepts in Laboratory Testing to Guide Antimicrobial TherapyCurrent Concepts in Laboratory Testing to Guide Antimicrobial Therapy
Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy
 
Case control
Case controlCase control
Case control
 
How evidence affects clinical practice in egypt
How evidence affects clinical practice in egyptHow evidence affects clinical practice in egypt
How evidence affects clinical practice in egypt
 
Epcm l9(new) screening for diseases
Epcm l9(new) screening for diseasesEpcm l9(new) screening for diseases
Epcm l9(new) screening for diseases
 
Impact Of Computer Software Appplication On Medication Therapy Adherence
Impact Of Computer Software Appplication On Medication Therapy AdherenceImpact Of Computer Software Appplication On Medication Therapy Adherence
Impact Of Computer Software Appplication On Medication Therapy Adherence
 
Diagnosis Of Hep C Update Aug%20 09pdf
Diagnosis Of Hep C Update Aug%20 09pdfDiagnosis Of Hep C Update Aug%20 09pdf
Diagnosis Of Hep C Update Aug%20 09pdf
 
C04 P02 CRITERIA FOR SCREENING TESTS.ppt
C04 P02 CRITERIA FOR SCREENING TESTS.pptC04 P02 CRITERIA FOR SCREENING TESTS.ppt
C04 P02 CRITERIA FOR SCREENING TESTS.ppt
 

Más de Chau Nguyen

Urinary tract infections
Urinary tract infections Urinary tract infections
Urinary tract infections Chau Nguyen
 
Lisa scientific facts of losing weight
Lisa scientific facts of losing weightLisa scientific facts of losing weight
Lisa scientific facts of losing weightChau Nguyen
 
Lisa heath nutrition diet and diabetes prevention lisa
Lisa heath nutrition diet and diabetes prevention lisaLisa heath nutrition diet and diabetes prevention lisa
Lisa heath nutrition diet and diabetes prevention lisaChau Nguyen
 
Dr liu quit smoking slides 1 26-2013
Dr liu quit smoking slides 1 26-2013Dr liu quit smoking slides 1 26-2013
Dr liu quit smoking slides 1 26-2013Chau Nguyen
 
Dr liu life chinese version
Dr liu life chinese versionDr liu life chinese version
Dr liu life chinese versionChau Nguyen
 
Dr liu fibromyalgia disease overview-1
Dr liu fibromyalgia disease overview-1Dr liu fibromyalgia disease overview-1
Dr liu fibromyalgia disease overview-1Chau Nguyen
 
Dr liu diabetes community education
Dr liu diabetes community educationDr liu diabetes community education
Dr liu diabetes community educationChau Nguyen
 
Dr liu diabetes and pain
Dr liu diabetes and painDr liu diabetes and pain
Dr liu diabetes and painChau Nguyen
 
Dr liu depression
Dr liu depressionDr liu depression
Dr liu depressionChau Nguyen
 
Dr liu 12 8-2012 updike-risk management and pt assessment in pm
Dr liu 12 8-2012  updike-risk management and pt assessment in pmDr liu 12 8-2012  updike-risk management and pt assessment in pm
Dr liu 12 8-2012 updike-risk management and pt assessment in pmChau Nguyen
 
Dr liu 10 20-2012 anxiety
Dr liu 10 20-2012 anxietyDr liu 10 20-2012 anxiety
Dr liu 10 20-2012 anxietyChau Nguyen
 
Dr liu 1 19-2013 obesity
Dr liu 1 19-2013 obesity Dr liu 1 19-2013 obesity
Dr liu 1 19-2013 obesity Chau Nguyen
 
Chiamaka diabetes presentation
Chiamaka  diabetes presentationChiamaka  diabetes presentation
Chiamaka diabetes presentationChau Nguyen
 
An opportunistic pathogen isolated from the gut of
An opportunistic pathogen isolated from the gut ofAn opportunistic pathogen isolated from the gut of
An opportunistic pathogen isolated from the gut ofChau Nguyen
 

Más de Chau Nguyen (20)

Urinary tract infections
Urinary tract infections Urinary tract infections
Urinary tract infections
 
Sally breakfast
Sally breakfastSally breakfast
Sally breakfast
 
Qysmia
QysmiaQysmia
Qysmia
 
Qsymia
QsymiaQsymia
Qsymia
 
Presentation 4
Presentation 4Presentation 4
Presentation 4
 
Presentation 3
Presentation 3Presentation 3
Presentation 3
 
Lisa scientific facts of losing weight
Lisa scientific facts of losing weightLisa scientific facts of losing weight
Lisa scientific facts of losing weight
 
Lisa heath nutrition diet and diabetes prevention lisa
Lisa heath nutrition diet and diabetes prevention lisaLisa heath nutrition diet and diabetes prevention lisa
Lisa heath nutrition diet and diabetes prevention lisa
 
Dr. lui j
Dr. lui jDr. lui j
Dr. lui j
 
Dr liu quit smoking slides 1 26-2013
Dr liu quit smoking slides 1 26-2013Dr liu quit smoking slides 1 26-2013
Dr liu quit smoking slides 1 26-2013
 
Dr liu life chinese version
Dr liu life chinese versionDr liu life chinese version
Dr liu life chinese version
 
Dr liu fibromyalgia disease overview-1
Dr liu fibromyalgia disease overview-1Dr liu fibromyalgia disease overview-1
Dr liu fibromyalgia disease overview-1
 
Dr liu diabetes community education
Dr liu diabetes community educationDr liu diabetes community education
Dr liu diabetes community education
 
Dr liu diabetes and pain
Dr liu diabetes and painDr liu diabetes and pain
Dr liu diabetes and pain
 
Dr liu depression
Dr liu depressionDr liu depression
Dr liu depression
 
Dr liu 12 8-2012 updike-risk management and pt assessment in pm
Dr liu 12 8-2012  updike-risk management and pt assessment in pmDr liu 12 8-2012  updike-risk management and pt assessment in pm
Dr liu 12 8-2012 updike-risk management and pt assessment in pm
 
Dr liu 10 20-2012 anxiety
Dr liu 10 20-2012 anxietyDr liu 10 20-2012 anxiety
Dr liu 10 20-2012 anxiety
 
Dr liu 1 19-2013 obesity
Dr liu 1 19-2013 obesity Dr liu 1 19-2013 obesity
Dr liu 1 19-2013 obesity
 
Chiamaka diabetes presentation
Chiamaka  diabetes presentationChiamaka  diabetes presentation
Chiamaka diabetes presentation
 
An opportunistic pathogen isolated from the gut of
An opportunistic pathogen isolated from the gut ofAn opportunistic pathogen isolated from the gut of
An opportunistic pathogen isolated from the gut of
 

A tiered approach to integrating genomic tests into

  • 1. A Tiered Approach to Integrating Genomic Tests Into Your Practice
  • 2. Definition Tiered Approach: Types Genomic Tests: DNA screening test Practice: Giving a diagnosis and prescribing a treatment for medical condition Combine DNA screening with medical treatment to test the probability of certain disease.
  • 3. Initiation Office of Public Health Genomics at the Centers for Disease Control and Prevention (CDC)
  • 4. A New Era Medicine informed by new "personalization" tools in diagnosis, management, and prevention of many diseases of public health significance. However, The mere availability of a health application does not necessarily imply evidence of efficacy.
  • 5. the CDC Office of Public Health Genomics has recently created an evolving list of health- related genomic tests and family health history applications 3 Tier
  • 6. 1st Tier
  • 7. 1st Tier Applications are recommended for clinical use by evidence-based panels and are supported by a systematic review of evidence establishing the validity and utility of these tests for their intended use.
  • 8. • Newborn screening • BRCA1 and BRCA2 • Colorectal cancer surveillance
  • 9. • evidence-based recommendation from the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) http://www.egappreviews.org/recommendations/index.htm
  • 10. 2nd Tier
  • 11. 2nd Tier Applications have evidence establishing validity and promising utility, but they lack evidence- based recommendations for their use, or evidence-based panels have simply found insufficient evidence.
  • 12. • pharmacogenomic testing individualization of the choice or dose of a drug. • Family history of Diabetes Mellitus
  • 13. 3rd Tier Genomic and family health history applications have not demonstrated adequate analytic validity, clinical validity, or clinical utility.
  • 14. Such applications are not ready for routine practice but may be considered in clinical and population research. • whole genome sequencing/next-generation sequencing
  • 15. Summary "personalization“ Prevention Ẋ ready for "prime time.“ Ẋ Lack of evidence
  • 16. Web Resources CDC. Public Health Genomics. Genetic Testing CDC. Tier 1 Genomic and Family Health History Applications. CDC. Tier 2 Genomic and Family Health History Applications. CDC. Tier 3 Genomic and Family Health History Applications.
  • 17. Michael Scott Bowen Scott Bowen is the deputy director of the Office of Public Health Genomics. He earned his Masters of Public Health degree in Epidemiology from Tulane University. Mr. Bowen came to CDC under the Outstanding Scholar Program in 1992 and had previously served on active duty as a non-commissioned officer with the U.S. Army. His past CDC roles included service as the Management Officer for the CDC/OD offices and as the deputy director for the Division of Public Health Surveillance and Informatics. He has also worked for the Agency for Toxic Substances and Disease Registry where he served as an epidemiologist and as deputy chief of the Health Investigations Branch.